Monday, 16 Sep 2019

You are here

Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

The approved once daily dose is 15 mg qd. The drug may be used with MTX or other DMARDs but should not be combined with other JAK inhibitors or biologic agents.

There is a Boxed Warning for serious infection, malignancy and thrombosis risks:

  • Serious infections including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections
  • Hold RINVOQ if a serious infection develops and until the infection is controlled
  • Test for latent tuberculosis prior to starting RINVOQ; if positive, start TB treatment prior to starting RINVOQ
  • Monitor all patients for active tuberculosis during treatment
  • Lymphoma and other malignancies have been observed in patients treated with RINVOQ
  • Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with RINVOQ

Other precautions and warnings include:

  • Avoid initiation or interrupt RINVOQ if: A) absolute lymphocyte count is less than 500 cells/mm3; B) absolute neutrophil count is less than 1000 cells/mm3 or C) hemoglobin level is less than 8 g/dL
  • Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately
  • Use with caution in patients who may be at increased risk for gastrointestinal perforations
  • RINVOQ may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

The full package insert information can be found here https://buff.ly/307rKXv

AbbVie has announced that Rinvoq will be available at a list price $59,000 a year (or $5,174 a month). d on the duration of the treatment and individual healthcare plans. As expected, there will be a co-pay card to reduce out-of-pocket costs to $5 per month for eligible, commercially-insured patients, and a patient support program as well. By comparison, wholesale cost for Humira is $62,088. For Xeljanz is $53,772. Olumiant (relatively cheaper) is $25,642.  

This is the third JAK inhibitor to be FDA approved for use in RA.

Rinvoq (upadacitinib) is also being studied for use in other conditions such as psoriatic arthritis, Crohn’s disease and ulcerative colitis.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.

Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

Rituximab Safety Concerns when Used in anti-TNF Refractory RA

The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.

No Difference Among Biologics in Arthroplasty Infectious Risk

A large administrative claims analysis of rheumatoid arthritis (RA) patients undergoing arthroplasty has shown no difference among biologics with regard to the risk of infections, but corticosteroid use was associated with a dose dependent risk of infection. 

The Annals of Internal Medicine has published an analysis of peri- and postoperative infectious risk among RA patients receiving biologics or glucocorticoids.